1071 related articles for article (PubMed ID: 26703005)
21. Limited radiographic progression and sustained reductions in MRI inflammation in patients with axial spondyloarthritis: 4-year imaging outcomes from the RAPID-axSpA phase III randomised trial.
van der Heijde D; Baraliakos X; Hermann KA; Landewé RBM; Machado PM; Maksymowych WP; Davies OR; de Peyrecave N; Hoepken B; Bauer L; Nurminen T; Braun J
Ann Rheum Dis; 2018 May; 77(5):699-705. PubMed ID: 29343510
[TBL] [Abstract][Full Text] [Related]
22. Adalimumab for the treatment of ankylosing spondylitis and nonradiographic axial spondyloarthritis - a five-year update.
Poddubnyy D; Rudwaleit M
Expert Opin Biol Ther; 2013 Nov; 13(11):1599-611. PubMed ID: 24074224
[TBL] [Abstract][Full Text] [Related]
23. An appraisal of golimumab in the treatment of severe, active nonradiographic axial spondyloarthritis.
Paccou J; Flipo RM
Drug Des Devel Ther; 2016; 10():2255-62. PubMed ID: 27468228
[TBL] [Abstract][Full Text] [Related]
24. The term 'non-radiographic axial spondyloarthritis' is much more important to classify than to diagnose patients with axial spondyloarthritis.
Deodhar A; Strand V; Kay J; Braun J
Ann Rheum Dis; 2016 May; 75(5):791-4. PubMed ID: 26768406
[TBL] [Abstract][Full Text] [Related]
25. Should axial spondyloarthritis without radiographic changes be treated with anti-TNF agents?
Keat A; Bennett AN; Gaffney K; Marzo-Ortega H; Sengupta R; Everiss T
Rheumatol Int; 2017 Mar; 37(3):327-336. PubMed ID: 28035438
[TBL] [Abstract][Full Text] [Related]
26. Predictive factors for partial remission according to the Ankylosing Spondylitis Assessment Study working group in patients with ankylosing spondylitis treated with anti-TNFα drugs.
Perrotta FM; Addimanda O; Ramonda R; D'Angelo S; Lubrano E; Marchesoni A; Olivieri I; Punzi L; Salvarani C; Spadaro A
Reumatismo; 2014 Nov; 66(3):208-14. PubMed ID: 25376955
[TBL] [Abstract][Full Text] [Related]
27. Comparison of ankylosing spondylitis and non-radiographic axial spondyloarthritis in a multi-ethnic Asian population of Singapore.
Hong C; Kwan YH; Leung YY; Lui NL; Fong W
Int J Rheum Dis; 2019 Aug; 22(8):1506-1511. PubMed ID: 31090201
[TBL] [Abstract][Full Text] [Related]
28. Cancer risk in patients with spondyloarthritis treated with TNF inhibitors: a collaborative study from the ARTIS and DANBIO registers.
Hellgren K; Dreyer L; Arkema EV; Glintborg B; Jacobsson LT; Kristensen LE; Feltelius N; Hetland ML; Askling J;
Ann Rheum Dis; 2017 Jan; 76(1):105-111. PubMed ID: 27147709
[TBL] [Abstract][Full Text] [Related]
29. Discriminant validity, responsiveness and reliability of the arthritis-specific Work Productivity Survey assessing workplace and household productivity within and outside the home in patients with axial spondyloarthritis, including nonradiographic axial spondyloarthritis and ankylosing spondylitis.
Osterhaus JT; Purcaru O
Arthritis Res Ther; 2014 Aug; 16(4):R164. PubMed ID: 25099160
[TBL] [Abstract][Full Text] [Related]
30. Clinical improvement and reduction in serum calprotectin levels after an intensive exercise programme for patients with ankylosing spondylitis and non-radiographic axial spondyloarthritis.
Levitova A; Hulejova H; Spiritovic M; Pavelka K; Senolt L; Husakova M
Arthritis Res Ther; 2016 Nov; 18(1):275. PubMed ID: 27887637
[TBL] [Abstract][Full Text] [Related]
31. Treatment of ankylosing spondylitis with TNF inhibitors does not have adverse effect on results of liver function tests: a longitudinal study.
Capkin E; Karkucak M; Cosar AM; Ak E; Karaca A; Gokmen F; Budak BS; Tosun M
Int J Rheum Dis; 2015 Jun; 18(5):548-52. PubMed ID: 24612551
[TBL] [Abstract][Full Text] [Related]
32. Clinical and economic burden of extra-articular manifestations in ankylosing spondylitis patients treated with anti-tumor necrosis factor agents.
Gao X; Wendling D; Botteman MF; Carter JA; Rao S; Cifaldi M
J Med Econ; 2012; 15(6):1054-63. PubMed ID: 22563743
[TBL] [Abstract][Full Text] [Related]
33. Cross-sectional study of patients with axial spondyloarthritis fulfilling imaging arm of ASAS classification criteria: baseline clinical characteristics and subset differences in a single-centre cohort.
Bubová K; Forejtová Š; Zegzulková K; Gregová M; Hušáková M; Filková M; Hořínková J; Gatterová J; Tomčík M; Szczuková L; Pavelka K; Šenolt L
BMJ Open; 2019 Apr; 9(4):e024713. PubMed ID: 30944131
[TBL] [Abstract][Full Text] [Related]
34. Elevated faecal calprotectin is linked to worse disease status in axial spondyloarthritis: results from the SPARTAKUS cohort.
Olofsson T; Lindqvist E; Mogard E; Andréasson K; Marsal J; Geijer M; Kristensen LE; Wallman JK
Rheumatology (Oxford); 2019 Jul; 58(7):1176-1187. PubMed ID: 30649509
[TBL] [Abstract][Full Text] [Related]
35. Ankylosing spondylitis and nonradiographic axial spondyloarthritis: part of a common spectrum or distinct diseases?
Wallis D; Haroon N; Ayearst R; Carty A; Inman RD
J Rheumatol; 2013 Dec; 40(12):2038-41. PubMed ID: 24187102
[TBL] [Abstract][Full Text] [Related]
36. Erythrocyte sedimentation rate, C-reactive protein level, and serum amyloid a protein for patient selection and monitoring of anti-tumor necrosis factor treatment in ankylosing spondylitis.
de Vries MK; van Eijk IC; van der Horst-Bruinsma IE; Peters MJ; Nurmohamed MT; Dijkmans BA; Hazenberg BP; Wolbink GJ
Arthritis Rheum; 2009 Nov; 61(11):1484-90. PubMed ID: 19877087
[TBL] [Abstract][Full Text] [Related]
37. Baseline predictors of response and discontinuation of tumor necrosis factor-alpha blocking therapy in ankylosing spondylitis: a prospective longitudinal observational cohort study.
Arends S; Brouwer E; van der Veer E; Groen H; Leijsma MK; Houtman PM; Th A Jansen TL; Kallenberg CG; Spoorenberg A
Arthritis Res Ther; 2011 Jun; 13(3):R94. PubMed ID: 21689401
[TBL] [Abstract][Full Text] [Related]
38. Which factors influence radiographic progression during treatment with tumor necrosis factor inhibitors in clinical practice? Results from 930 patients with rheumatoid arthritis in the nationwide Danish DANBIO registry.
Ørnbjerg LM; Østergaard M; Bøyesen P; Krogh NS; Thormann A; Tarp U; Poulsen UE; Espesen J; Schlemmer A; Graudal N; Kollerup G; Jensen DV; Madsen OR; Glintborg B; Christensen T; Lindegaard H; Bøhme W; Hansen A; Andersen AR; Hetland ML
J Rheumatol; 2014 Dec; 41(12):2352-60. PubMed ID: 25274894
[TBL] [Abstract][Full Text] [Related]
39. Clinical response, drug survival and predictors thereof in 432 ankylosing spondylitis patients after switching tumour necrosis factor α inhibitor therapy: results from the Danish nationwide DANBIO registry.
Glintborg B; Østergaard M; Krogh NS; Tarp U; Manilo N; Loft AG; Hansen A; Schlemmer A; Fana V; Lindegaard HM; Nordin H; Rasmussen C; Ejstrup L; Jensen DV; Petersen PM; Hetland ML
Ann Rheum Dis; 2013 Jul; 72(7):1149-55. PubMed ID: 22941767
[TBL] [Abstract][Full Text] [Related]
40. The effect of comedication with conventional synthetic disease modifying antirheumatic drugs on TNF inhibitor drug survival in patients with ankylosing spondylitis and undifferentiated spondyloarthritis: results from a nationwide prospective study.
Lie E; Kristensen LE; Forsblad-d'Elia H; Zverkova-Sandström T; Askling J; Jacobsson LT;
Ann Rheum Dis; 2015 Jun; 74(6):970-8. PubMed ID: 25710471
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
